By LINDA A. JOHNSON
AP Medical Writer
U.S. regulators have approved a new medicine for treating a common type of breast cancer that has spread to other parts of the body.
Eli Lilly's Verzenio (verr-ZEHN'ee-oh) was approved Thursday by the Food and Drug Administration for patients with what's called HR-positive, HER2-negative breast cancer that has worsened after hormone therapy.
According to the FDA, about 72 percent of patients with breast cancer have this type.
The daily pill is to be used either alone, after hormone therapy and chemotherapy have stopped working, or in combination with a hormone therapy called fulvestrant.
Indianapolis-based Eli Lilly says Verzenio, which is taken until cancer resumes growing, will cost $10,948 per month. It's offering patients financial assistance, including 12 months with a minimal copayment for those with commercial insurance.
Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- FDA approves Lilly pill for common advanced breast cancer
- FDA approves Eli Lilly pill for common advanced breast cancer
- FDA approves first immunotherapy regimen for breast cancer
- FDA approves preventive migraine treatment
- FDA approves powerful new opioid
- FDA OKs powerful opioid pill as alternative to IV painkiller
- Warrior Workouts to benefit breast cancer patients
- Rose-Hulman Tusk Triathlon supports breast cancer
- FDA approves first postpartum depression drug
- Breast cancer group paints ribbon on National Cancer Survivors Day